e l f Beauty Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? e l f Beauty Inc trades at $107.6 (market cap $6.38B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 26 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| ELF | HNGE | |
|---|---|---|
Market Cap | $6.38B | $8.48B |
Volume | 856,198 | 879,799 |
Sector | Consumer Staples | Health |
52-Week High | $136.92 | $105.14 |
52-Week Low | $49.57 | $31.17 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $6.97B | $8.10B |
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum showing bullish moving averages but overbought RSI readings. The company demonstrates robust revenue growth with Q2 2026 earnings beating expectations by 145%, though valuation metrics remain elevated with a P/E of 110.37. Recent expansion includes rhode brand launches in 19 European markets via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album.
Outlook remains positive with analyst consensus leaning bullish (48% buy ratings) despite premium valuation. Key opportunities include international expansion and market share gains, while risks center on margin compression and competitive pressures in the beauty sector. The stock trades above consensus price target of $95.91, suggesting near-term consolidation potential.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →